GM 1485

Drug Profile

GM 1485

Alternative Names: GM-1485; GPI-1485; NIL-A

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MGI GP
  • Developer GliaMed
  • Class Lactones; Macrolides; Neuroprotectants; Small molecules
  • Mechanism of Action Immunophilin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Wounds
  • Discontinued Dementia; Erectile dysfunction; HIV-associated nephropathy; Parkinson's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Wounds in USA (Topical)
  • 31 Aug 2009 Preclinical trials in Wounds in USA (Topical)
  • 04 Sep 2007 Discontinued - Phase-II for Erectile dysfunction in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top